Drug intelligence / Profile preview

GS102

Development stage: Preclinical
Lead developer: Jiangsu Genscend Biopharmaceutical
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous, Subcutaneous

Overview

GS102 is a preclinical monoclonal antibody biosimilar of risankizumab (Skyrizi) being developed by Jiangsu Genscend Biopharmaceutical for the treatment of autoimmune diseases. It selectively targets the p19 subunit of interleukin-23 (IL-23), thereby preventing IL-23 from binding to its receptor and blocking downstream inflammatory signaling pathways. The candidate is currently in preclinical/IND-enabling development, with an IND filing projected for Q2 2027 and a BLA filing planned for Q1 2030.

Other names: Risankizumab biosimilar

Targets

IL23A (Interleukin-23 p19 Subunit)IL23R (Interleukin-23 Receptor)FcγR (Low affinity immunoglobulin gamma Fc region receptor II-c)FCGRT (Neonatal crystallizable fragment receptor)

Beyond the preview

Go deeper on GS102.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GS102.

Explore the full profile